Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Paul Hudson, CEO of Sanofi, has been driving an all-encompassing effort to use AI to reshape the way the company ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the ...

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...

Paul Hudson, CEO of Sanofi, works in a volatile business. The pharma sector has been very profitable for many decades, and its weight in the economy has grown steadily.

Sanofi CEO Paul Hudson speaks during the Competing In The Global Marketplace: Strategies for Growth panel, at the Fortune Global Forum on Nov. 11, 2024 in New York City. (Jemal Countess—Getty ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Sanofi CEO Paul Hudson on the potential for AI to drive insights and better decision intelligence in the pharmaceutical industry.

Sanofi (NASDAQ:SNY) 39th Annual JPMorgan Virtual Healthcare Conference January 12, 2021 11:40 AM ETCompany ParticipantsPaul Hudson - CEOArnaud Robert - ...